CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on ...

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $42.5 and $55.0 for CRISPR Therapeutics, spanning the last three ...

CRISPR Therapeutics: 2025 TIME100 Most Influential CompaniesCRISPR Therapeutics is a biotech company that borrows its name from the groundbreaking gene editing technology CRISPR. As of last year ...

A Ph.D. student in biomolecular engineering at the University of California, Santa Cruz, has built a software program ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 7.26%. Read on to learn why. Crispr Therapeutics AG has seen a notable ...

CRISPR Therapeutics (NASDAQ:CRSP) operates within the biotechnology segment, which remains active across key indices like the ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will ...

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large markets. Click for my CRSP update.

With half a million people having already received multi-cancer early detection (MCED) screening, patients are and will continue to be asking about these blood tests during their visits, physicians ...